NOV 0 3 2004,

1 FW

Docket No. 2003-003R1

PATENT

1639

Examiner: Unknown

Group Art Unit:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

BY: Annie Wong

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Carlson	et al.
-----------------------	---------	--------

Serial No.: 10/790,956

Filed: March 1, 2004

For: Evaluating Effects of Exposure

Conditions on Drug Samples Over Time

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith (check all that apply):

[X] Supplemental Information Disclosure Statement
[] Petition Under 37 CFR 1.97(d)(2)
[] Formal Drawings
[] Declaration Under 37 CFR 1.131
[] Declaration Under 37 CFR 1.132
[] Terminal Disclaimer
[] Small Entity Statement
[] Request for Refund
[] Appeal
[] Petition
[] Status Letter
lication.

[X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0496.

A duplicate copy of this Transmittal Letter is transmitted herewith.

Respectfully submitted,

Reg. No. 45,695 Attorney for Applicant(s)

lo /20/24

Symyx Technologies, Inc. 3100 Central Expressway Santa Clara, California 95051

Tel.: (408) 720-2598 Fax: (408) 773-4029

Docket No. 2003-003R1 PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to:

Openinissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 111104

Annie Wong

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Carlson et al. Confirmation No. 2161

Serial No.: 10/790,956 Group Art Unit: 1639

Filed: March 1, 2004 Examiner: Unknown

For: Evaluating Effects of Exposure

Conditions on Drug Samples Over Time

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith patents, publications and other information of which they are aware, which they believe an examiner may consider to be material to the patentability of the claims of this application, and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

While this Information Disclosure Statement may contain "material" information pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is either "material" or "prior art" to the invention disclosed and claimed in the above-referenced application unless specifically designated as such. Applicants specifically reserve the right, where appropriate, to avoid or antedate any such reference by the appropriate arguments or showings under 37 C.F.R. § 1.131 and § 1.608, or any other appropriate means.

A completed PTO Form 1449 listing each reference is submitted herewith, and it is respectfully requested that an Examiner initialed copy of the PTO Form 1449 be returned to the undersigned. Copies of each reference listed on the PTO Form 1449 are enclosed except for copies of the U.S. patent documents which are not supplied in accordance with the OG notice of August 5, 2003, partially waiving the requirements of 37 C.F.R. §1.98(a)(2)(i).

Docket No. 2003-003R1 PATENT

This Information Disclosure Statement is being filed within three months of the filing or entry of the national stage of this application, or before the mailing of a first Office Action on the merits, whichever is later. No fee is required under 37 C.F.R. § 1.97(b). However, in the event that more than 90 days from filing have elapsed and a first Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the fee required under 37 C.F.R. 1.17(p) to Deposit Account Number 50-0496.

The Examiner is hereby requested to consider these references and other information and make them of record in the above-referenced application. Applicants respectfully submit that the claims of this application are patentable over the above-cited references and information. Examination and allowance of this application at an early date are requested.

Respectfully submitted,

James H. Ackley, Registration No. 45,695

Date:

Symyx Technologies, Inc. 3100 Central Expressway Santa Clara, CA 95051

Tel: (408) 720-2598 Fax: (408) 773-4029

				ATTORNEY'S DOCKET NO.:			APPLICATION NO.:			
INFORMATION DISCLOSURE CITATION		2003-003R1			10/790,956					
OIP	E 20-1449	,	APPLICANT:							
1101 0 3 2004 H			Carlson et al.							
IN SECTION					Confi 2161	IRMATION NO.:	GROUP: 1639			
9 TH	ADL	US PA	TENT DOCUM	/ENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAM	ΜE	CLA	SS	SUBCLASS	FILING DATE		
							<u> </u>			
			+							
			 							
			 							
			 				ļ			
		FORE	EIGN DOCUMI	ENTS			<u> </u>			
EXAMINER'S	1	TONE	T	ENIO		—	SUB T	TRANSLATION		
INITIALS	PATENT NO.	DATE		JNTRY		ASS	CLASS	Yes No		
	WO 02/077614	10/3/2002	PCT		G01		13/00			
	WO 03/014732	2/20/2003	PCT		G01	N	33/48			
					$oxed{oxed}$					
					$I_{\underline{}}$					
	OTHER DOCUME		<u> </u>							
	Abdel-Hamid., "Applica Multicomponent Analys pp. 2719-2735									
	Dong et al., Study on the Fluorescence Characteristics of Alkaline Degradation of Cefadroxil, Cephradine, Cefotaximum Sodium and Amoxicillini", <i>Analytical Letters</i> , 31(6), 1998, pp. 1047-1060									
	Grant et al., "Influence of Water Activity in Organic Solvent + Water Mixtures on the Nature of the Crystallizing Drug Phase. 2. Ampicillin", <i>International Journal of Pharmaceutics</i> , 139, 1996, pp. 33-43									
	Schallreuter et al., Óxybenzone Oxidation Following Solar Irradiation of Skin: Photoprotection versus Antioxidant Inactivation", <i>The Journal of Investigative Dermatology</i> , 106(3), 1996, pp. 583-586									
	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LA/									
EXAMINER:	/Lyle Alexander/			DATE CONSID	DERED:	:	06/17/2008	8		

Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.